blood product – CRI Report https://www.cri-report.com market research vender! Tue, 21 Aug 2018 03:12:34 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg blood product – CRI Report https://www.cri-report.com 32 32 Research Report on China Blood Product Industry, 2011-2016 https://www.cri-report.com/research-report-on-china-blood-product-industry-2011-2016/ Fri, 17 Aug 2018 09:06:06 +0000 https://www.cri-report.com/product/import-placeholder-for-1604337/ In 2015, 8,000 tons of blood plasma was needed to meet the demand of Chinese market, and the actual supply was only 5,000 tons.

The post Research Report on China Blood Product Industry, 2011-2016 first appeared on CRI Report.

]]> Description

Blood products made by segregating and purifying all kinds of proteins in the blood plasma consists of albumin, immunoglobulin, thrombinogen and other products. China’s enterprises mainly produce 9 kinds of products in the first three categories.

The high concentration rate of the global blood product market is embodied in the three companies of developed countries accounting for more than 80% of the global market. The current global blood market remains relatively stable, of which the emerging economy is the main motivation of growth.

By the end of 2015, there were 33 blood product manufacturing enterprises certified by the government in China, but in fact, only 20 of them were in production. Since 2012, mergers and acquisitions are common in China’s blood product industry. For example, Jiangxi Boya Bio-Pharmaceutical Co., Ltd. acquired partial stock rights of Zhejiang Haikang Biologicals Co., Ltd. Beijing Tiantan Biological Products Co., Ltd. purchased Chengdu Rosen Pharmaceutical Co., Ltd. Watson Biological Company acquired Hebei Docan Pharmaceutical Co., Ltd. Shanghai RAAS Blood Products Co., Ltd. purchased Zhengzhou Banghe Pharmaceutical Co., Ltd. China National Biotec Group acquired Guiyang Qianfeng Biological Products Co., Ltd. and Xi’an Huitian Blood Products Co., Ltd. Humanwell Healthcare Group Co., Ltd. purchased Wuhan Rui De Biological Products Co., Ltd.

In 2015, 8,000 tons of blood plasma was needed to meet the demand of Chinese market, and the actual supply was only 5,000 tons. For example, the demand for blood products of about 1.4 billion population of China should be 12,000 tons calculated according to per capita demand of the normal blood products of the World Health Organization, which is far more than the actual supply of China.

In China’s blood product industry, the scale of the blood plasma has been the main bottleneck restricting the development of blood product industry. The quality and quantity of plasma stations are of vital importance.

In 2001, Chinese government announced that no new blood product manufacturing enterprises would be approved to ensure the safety of blood and its products, and block the spread of HIV through collection and supply of blood .

In 2008, Chinese government formulated the regulations that the plasma collection regions should guarantee the quantity of the plasma donors, which can satisfy no less than 30 tons’ collection of source plasma.

In 2011, Guizhou government announced the program of adjusting the settings of blood services. The plasma collection stations decreased from 20 to 4, of which Hualan Biological Engineering Co., Ltd., the blood product giant, suffered the most. The plasma stations of Guizhou Province decreased from 6 to 1, having reduced half of the corporate source plasma supply.

Lack of the local blood products, but Chinese government has issued strict regulations on the import of blood products. Only human serum albumin and three kinds of thrombinogen are allowed to be imported.

In recent years, the competitiveness of China’s blood product market has been mainly determined by the amount of blood plasma resources. Under the tense condition of source plasma supply, blood product manufacturing enterprises will obtain more space for survival and development with more blood plasma stations and source plasma.

On June 1, 2015, China National Development and Reform Commission released the highest price limit on blood products, and companies can name their own prices. In the first quarter of 2016, the price of fibrinogen and tetanus immunoglobulin in Chinese market increases  by 80%-130%, and the price of intravenous gammaglobulin increases by 10%-20%. In addition to the relaxed price regulations, another support policy is to gradually release the auditing of plasma collection stations. At the beginning of 2013, Chinese government released the auditing standards for plasma collection stations. By the end of 2013, there had been no more than 160 plasma collection stations in China. There were more than 200 plasma collection stations at the end of 2015. In spite of the most plasma collection stations, Shanghai RAAS Blood Products Co. Ltd. had possessed only 30 plasma collection stations in operation by the end of 2015.

In the long run, the competitiveness of blood product manufacturing enterprises mainly depends on the ability of research & development and sales. In a few years, the tense situation of China’s raw blood plasma’s supply will be eased. Only enterprises with strong ability of research & development and sales and a sound product line can win the competition.

There are only two channels for overseas blood product enterprise to enter Chinese market. One is to export products to China directly. The other one is to enter Chinese market indirectly through such means as equity acquisition.

The report is accomplished on the basis of deep market research. Through this report, the readers shall acquire the following information:

-Current Situation of the Global Blood Product Industry

-Development History and Current Situation of China’s Blood Products

-Government Policies of China’s Blood Product Industry

-Niche Products’ Current Situation of China’s Blood Product

-Market Competition of China’s Blood Product Industry

-China’s Major Blood Product Enterprises and Their Operation Status

-Development Trend of China’s Blood Product Industry

 

The Following Enterprises and People Are Recommended to Purchase This Report:

-Blood Product Manufacturing Enterprises

-Blood Product Regulatory Agency

-Investors /Research Agencies Focusing on Blood Product Industry

 

Table of Contents

1 Introduction of Blood Products

1.1 Definition

1.2 Characteristics

1.3 Classification

1.3.1 Albumin

1.3.2 Immune Globulin

1.3.3 Coagulation Factors

1.3.4 Other Categories

1.4 Industrial Policies on Blood Product

1.4.1 Industrial Competent Departments

1.4.2 Policies on Enterprise Establishment

1.4.3 Policies on Raw Material Purchasing

1.4.4 Policies on Blood Product Production

1.4.5 Policies on Blood Product Circulation

1.5 Overview on China Blood Product Industry

1.5.1 Regulatory Policies

1.5.2 Blood Utilization Ratio

1.5.3 Industry Characteristics

 

2 Overview of Global Blood Product Industry, 2011-2015

2.1 Industry Overview

2.1.1 Development Process

2.1.2 Competition Pattern

2.1.3 Supply Status

2.1.4 Demand Status

2.2 Major Blood Product Manufacturers in the Globe (Except China)

2.2.1 Baxter International

2.2.2 CSL Behring

2.2.3 Grifols SA

 

3 Supply and Demand Status of China Blood Product Industry, 2011-2015

3.1 Development Process

3.2 Barriers to Entry

3.2.1 Policy Barriers

3.2.2 Blood Source Barrier

3.2.3 Technology and Quality Control Capability

3.3 Supply

3.3.1 Overview on Production Status

3.3.2 Major Blood Product Manufacturers in China

3.3.3 Production Capacity and Output Volume of Albumin

3.3.4 Production Capacity and Output Volume of Immune Globulin

3.3.5 Production Capacity and Output Volume of Coagulation Factor

3.4 Demand Status

3.4.1 Albumin

3.4.2 Immune Globulin

3.4.3 Coagulation Factors

 

4 Major Enterprises of China Blood Product Industry, 2011- 2015

4.1 Shanghai RAAS Blood Products Co. Ltd.

4.1.1 Enterprise Profile

4.1.2 Production Capacity

4.2 Hualan Biological Engineering Co., Ltd.

4.3 Beijing Tiantan Biological Products Co., Ltd. (Subsidiary of China National Biotec Group Company Limited)

4.4 Guangdong Shuanglin Bio-pharmaceutical Co., Ltd.

4.5 Jiangxi Boya Bio-pharmaceutical Co., Ltd.

4.6 Hunan Nanyue Pharmaceutical Co., Ltd.

4.7 Wuhan Rui De Biological Products Co., Ltd.

4.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

4.9 Green Cross  Biological Products Co., Ltd.

4.10 Guiyang Qianfeng Biological Products Co., Ltd.

4.11 Anhui Da’an Biological Products Co., Ltd.

4.12 Shenzhen Weiguang Biological Products Co., Ltd.

4.13 Shandong Taibang Products Co., Ltd.

4.14 Subordinate Institutions of Biological Products of China National Biotec Group

 

5 Forecast on Development of China Blood Product Industry, 2016-2020

5.1 Supply Forecast

5.1.1 Forecast on Plasma Volume

5.1.2 Forecast on Lot Release

5.1.3 Forecast on Production Capacity Expansion

5.2 Demand Forecast

5.2.1 Demand Trend Prediction

5.2.2 Prediction of Market Size

5.3 Forecast on Market Competition

5.3.1 Forecast on Popular Products

5.3.2 Forecast on Competition Pattern

 

Selected Charts

Chart Common Varieties and Functions of Albumin

Chart Common Varieties and Functions of Immune Globulin

Chart Common Varieties and Functions of Coagulation Factors

Chart Varieties and Functions of Other Blood Products

Chart Important Policies of China Blood Product Industry

Chart Top 5 Blood Product Enterprises in the World, 2015

Chart Global Blood Product Plasma Volume and Forecast, 2009- 2020

Chart Global Blood Product Market Scale and Forecast, 2009-2020

Chart Market Share by Region in the Globe

Chart Market Share by Category in the Globe

Chart Sales Scale of Baxter International Blood Products, 2011-2015

Chart Sales Scale of CSL Behring Blood Products, 2011-2015

Chart Sales Scale of  Grifols Blood Products, 2011-2015

Chart Blood Product Plasma Volume in China, 2009-2015

Chart Lot Release Volume of Blood Products in China, 2009-2015

Chart Major Blood Product Manufacturers in China

Chart Lot Release Volume of Albumin Products in China, 2009- 2015

Chart Lot Release Volume of Immune Globulin Products in China, 2009-2015

Chart Lot Release Volume of Coagulation Factor Products in China, 2009-2015

Chart Market Scale of China Blood Products, 2011-201528

Chart Market Scale of Albumin Blood Products in China, 2011-2015

Chart Market Scale of Immune Globulin Blood Products in China, 2011-2015

Chart Market Scale of Coagulation Factor Blood Products in China, 2011-2015

Chart Products of Shanghai RAAS Blood Products Co. Ltd.

Chart Plasma Volume of Shanghai RAAS Blood Products Co. Ltd., 2011-2015

Chart Plasma Collecting Stations Newly Approved by the Chinese after 2009

Chart Forecast on Plasma Volume in China, 2016-2020

Chart Forecast on Lot Release of China Blood Products, 2016-2020

Chart Comparison of Annual Blood Product Consumption Per Capita Between Developed Countries and China, 2015

Chart Forecast on the Market Scale of Blood Products in China, 2016-2020

Chart Forecast on the Market Scale of Albumin Products in China, 2016-2020

Chart  Forecast on the Market Scale of Immune Globulin Products in China, 2016- 2020

Chart Forecast on the Market Scale of Coagulation Factor Products in China, 2016-2020

The post Research Report on China Blood Product Industry, 2011-2016 first appeared on CRI Report.

]]> Research Report on Blood Product Industry in China, 2018-2022 https://www.cri-report.com/research-report-on-blood-product-industry-in-china-2018-2022/ Fri, 17 Aug 2018 09:05:53 +0000 https://www.cri-report.com/product/import-placeholder-for-1711569/ As a category of biological products, a blood product is a kind of biological active preparation manufactured based on health human blood plasma with biological techniques or plasma separation and purification technologies.

The post Research Report on Blood Product Industry in China, 2018-2022 first appeared on CRI Report.

]]> Description
As a category of biological products, a blood product is a kind of biological active preparation manufactured based on health human blood plasma with biological techniques or plasma separation and purification technologies. According to patients of different diseases, different contents of plasma protein are separated and manufactured into specific blood products. Blood products can be categorized into human serum albumin, human immunoglobulin and coagulation factors that have a widest variety of products.
The concentration rate of global blood product industry is rather high. The four enterprises of developed countries, CSL Behring, Baxter, Grifols and Octapharma, occupy over 80% of global market shares. Currently, the global blood industry maintains relatively stable, with emerging markets serving as major driving forces.
According to CRI, China will become one of the major global blood product markets as its economy develops. Chinese government imposes strict regulations on production, sales and import of blood products. In addition, the government implements a lot release system of biological products (including blood products and vaccines), compulsorily inspecting and verifying every batch of such products when leaving factory or being imported. Disqualified or disapproved products should not be on the market or imported.
According to market research by CRI, about 30 blood product manufacturers have been authenticated by the Chinese government by the end of 2017. But indeed, only 20 of them operate under normal production. Since 2012, mergers and acquisitions have emerged in China’s blood product industry. Examples include Jiangxi Boya Bio-Pharmaceutical Co., Ltd. purchasing partial stake of Zhejiang Haikang Biological Products Co., Ltd., Beijing Tiantan Biological Products Co., Ltd. acquiring Chengdu Rosen Pharmaceutical Co., Ltd. and Humanwell Healthcare Group Co., Ltd. acquiring Wuhan Rui De Biological Products Co., Ltd.
CRI estimates that at least 10,000 tons of blood plasma is needed to meet the demand of Chinese market in 2017, but the actual supply is only 7,000 tons. China’s annual volume of blood plasma represents approximately half of the volume of CSL Behring. In China, the only approach to legal collection of source plasma is plasma collection from blood product manufacturers. There have been less than 300 plasma collection stations in China by the end of 2017, located in 22 domestic regions and belonging to 20 blood product manufacturers. Lack of source plasma collection has always been a major restriction of the development of China’s blood product industry. In China, the competitiveness of blood product manufacturers is mainly determined by the reserve volume of blood plasma. Under the tense condition of source plasma supply, blood product manufacturers have more opportunities for survival and development through obtaining more blood plasma stations and source plasma.
Based on analysis of CRI, the Chinese government imposes strict regulations on the import of blood products despite the lack of local production volume of blood products. Only human serum albumin and reshaped human blood coagulation factor Ⅷ are allowed to be imported. China must rely on the import of human serum albumin due to the demand-supply gap exceeding over 50% in 2017. CSL Behring, Baxter, Grifols S.A. and Octapharma all export human serum albumin to China.
In 2001, the Chinese government announced that new blood product manufacturers would be no longer authenticated for the safety of blood and blood products. If overseas blood product manufacturers desire to enter Chinese market, they can either export their products directly to China or acquire existing blood product manufacturers in China. For example, in August 2017, CSL Behring spent USD 352 million on purchasing 80% stake of Wuhan Zhongyuan Rui De Biological Products Co., Ltd., a subsidiary of Humanwell Healthcare Group Co., Ltd. On the third of August, 2017, CSL officially announced that it had completed the deal with Humanwell and had taken over business operations of Rui De. CSL Behring temporarily launched only albumin on Chinese market. In order to introduce more products into China, localized production is the first choice. In the future, Rui De is expected to apply extensive expertise of CSL Behring in fields of plasma collection, production and R&D. In the meanwhile, CSL Behring is making efforts to improve the experience of domestic plasma donors. The company also plans to launch more coagulation factor products and establish more plasma collection stations by virtue of Rui De’s knowledge of Chinese market.
Analyzed by CRI, the market value of blood products exceeded CNY 20 billion in China in 2017, with an estimated CAGR of over 10% during 2018 and 2022.
This report is completed on a basis of deep market investigation. Readers can obtain the following information or more through this report:

– Status of Global Blood Product Industry
– Development Status of China Blood Product Industry
– Policy Environment and Lot Release System of China Blood Product Industry
– Status of Segmented China Blood Products
– Competition Status of China Blood Product Industry
– Major Blood Product Manufacturers in China and Their Operation Status
– Blood Products Exported from CSL Behring, Baxter, Grifols S.A. and Octapharma to China, 2013-2017
– Price Trend of Raw Materials and Finished Products in China Blood Product Industry
– Driving Forces and Market Opportunities of China Blood Product Industry, 2018-2022
– Risks and Challenges Faced by China Blood Product Industry, 2018-2022
– Forecast on Supply and Demand of Blood Products in China, 2018-2022

Table of Contents
Chapter I Basic Concept of Blood Products
1.1 Definition of Blood Products
1.2 Classification of Blood Products
1.2.1 Albumin
1.2.2 Immune Globulin
1.2.3 Coagulation Factors
1.2.4 Other Categories
1.3 Research Methods of Report
1.3.1 Parameters and Assumptions
1.3.2 Data Sources
1.3.3 About CRI

Chapter II Overview of Global Blood Product Industry, 2013-2017
2.1 Industry Overview
2.1.1 Development Process
2.1.2 Market Competition
2.1.3 Supply Status
2.1.4 Demand Status
2.2 Major Blood Product Manufacturers in the Globe
2.2.1 CSL Behring
2.2.2 Baxter
2.2.3 Grifols S.A.
2.2.4 Octapharma

Chapter III Operation Status of China Blood Product Industry, 2013-2017
3.1 Development Environment of China Blood Product Industry
3.1.1 Economy Environment
3.1.2 Policy Environment
 Administrative Departments
 Policies on Enterprise Establishment
 Policies on Raw Material Purchasing
 Policies on Blood Product Production
 Policies on Blood Product Circulation
3.1.3 Medical Environment
3.2 Barriers to Entry in China Blood Product Market
3.2.1 Policy Barriers
3.2.2 Blood Source Barriers
3.2.3 Technology and Quality Control Capability
3.3 Analysis on Supply of Blood Products in China, 2013-2017
3.3.1 Overview of Production Status
3.3.2 Analysis of Major Products
3.3.3 Production Capacity and Output Volume of Albumin
3.3.4 Production Capacity and Output Volume of Immunoglobulin
3.3.5 Production Capacity and Output Volume of Coagulation Factors
3.4 Analysis on Demand for Blood Products in China, 2013-2017
3.4.1 Albumin
3.4.2 Immune Globulin
3.4.3 Coagulation Factors
3.5 Competition Pattern of China Blood Product Industry
3.5.1 Bargaining Power of Upstream Suppliers
3.5.2 Bargaining Power of Downstream Clients
3.5.3 Competition in Blood Product Industry
3.5.4 Potential Entrants of Blood Product Industry
3.5.5 Substitutes of Blood Products
3.6 Analysis on Import and Export of Blood Products in China
3.6.1 Import
3.6.2 Export

Chapter IV Analysis of Major Blood Product Manufacturers in China, 2016-2018
4.1 Shanghai RAAS Blood Products Co., Ltd.
4.1.1 Enterprise Profile
4.1.2 Operation Status of Blood Products
(4.2-4.16 are similar to 4.1)
4.2 Hualan Biological Engineering Co., Ltd.
4.3 Beijing Tiantan Biological Products Co., Ltd.
4.4 Zhenxing Biopharmaceutical & Chemical Inc.
4.5 Jiangxi Boya Bio-pharmaceutical Co., Ltd.
4.6 Guangdong Weilun Bio-pharmaceutical Co., Ltd.
4.7 Walvax Biotechnology Co., Ltd.
4.8 Wuhan Rui De Biological Products Co., Ltd.
4.9 Shenzhen Weiguang Biological Products Co., Ltd.
4.10 Guangdong Shuanglin Bio-pharmaceutical Co., Ltd.
4.11 Hunan Nanyue Pharmaceutical Co., Ltd.
4.12 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.13 Green Cross (China) Biological Products Co., Ltd.
4.14 Guiyang Qianfeng Biological Products Co., Ltd.
4.15 Shandong Taibang Products Co., Ltd.
4.16 Subordinate Institutions of Biological Products of China National Biotec Group
4.17 Hebei Daan Pharmaceutical Co., Ltd.
4.18 Guangdong Danxia Bio-pharmaceutical Co., Ltd.
4.19 Harbin Pacific Bio-pharmaceutical Co., Ltd.
4.20 Shanxi Kangbao Biological Product Co., Ltd.

Chapter V Analysis on Blood Product Industry Chain in China, 2016-2018
5.1 Supply of Blood Plasma
5.1.1 Development Status of Plasma Collection Stations in China
5.1.2 Cost of Plasma Collection
5.2 Production of Blood Products
5.2.1 Analysis of Gross Profit Rate
5.2.2 Analysis of Cost Trend
5.3 Price Trend of Blood Products

Chapter VI Forecast on Development of China Blood Product Industry, 2018-2022
6.1 Factors Influencing the Development of China Blood Product Industry
6.1.1 Market Opportunities and Driving Forces
6.1.2 Risks and Challenges
6.2 Forecast on Supply of Blood Products in China, 2018-2022
6.2.1 Forecast on Production Capacity Expansion
6.2.2 Forecast on Lot Release
6.3 Forecast on Demand for Blood Products in China, 2018-2022
6.3.1 Forecast on Demand Trend
6.3.2 Forecast on Market Scale
6.3.3 Forecast on Demand of Niche Markets

Selected Charts
Chart Common Varieties and Functions of Albumin
Chart Common Varieties and Functions of Immune Globulin
Chart Common Varieties and Functions of Coagulation Factors
Chart Global Blood Product Plasma Volume and Forecast, 2012-2022
Chart Global Blood Product Market Scale and Forecast, 2012-2022
Chart Sales Scale of Baxter International Blood Products, 2013-2017
Chart Sales Scale of CSL Behring Blood Products, 2013-2017
Chart Sales Scale of Grifols Blood Products, 2013-2017
Chart Blood Product Plasma Volume in China, 2013-2017
Chart Lot Release Volume of Blood Products in China, 2013-2017
Chart Major Blood Product Manufacturers in China, 2018
Chart Lot Release Volume of Albumin Products in China, 2013-2017
Chart Lot Release Volume of Immune Globulin Products in China, 2013-2017
Chart Lot Release Volume of Coagulation Factor Products in China, 2013-2017
Chart Market Size of China Blood Products, 2013-2017
Chart Market Size of Albumin Blood Products in China, 2013-2017
Chart Market Size of Immune Globulin Blood Products in China, 2013-2017
Chart Products of Shanghai RAAS Blood Products Co. Ltd., 2018
Chart Lot Release Volume of Human Serum Albumin of Shanghai RAAS, 2012-2017
Chart Revenue of Shanghai RAAS Blood Products, 2013-2017
Chart Lot Release Volume of Human Serum Albumin of Hualan Biological, 2013-2017
Chart Lot Release Volume of Human Serum Albumin of CSL Behring, 2013-2017
Chart Lot Release Volume of Human Serum Albumin of Grifols, 2013-2017
Chart Lot Release Volume of Human Serum Albumin of Baxter, 2013-2017
Chart Lot Release Volume of Human Serum Albumin of Octapharma, 2013-2017
Chart Quantity of Plasma Collection Stations in China, 2013-2017
Chart Forecast on the Market Size of Blood Products in China, 2018-2022
Chart Forecast on the Market Size of Albumin Products in China, 2018-2022
Chart Forecast on the Market Size of Immune Globulin Products in China, 2018-2022
Chart Forecast on the Market Size of Coagulation Factor Products in China, 2018-2022

The post Research Report on Blood Product Industry in China, 2018-2022 first appeared on CRI Report.

]]>